Anthropic said Claude's Mythos Preview and Opus 4.8 models autonomously ran an end-to-end computational design pipeline that produced working protein binders against 14 of 15 targets, yielding 354 confirmed binders from 1,320 designs validated in the lab by partners Adaptyv Bio and Twist Bioscience. Hit rates reached 26.7% and 22.6% for the two models, well above the 10-15% typical for human-led protein-design campaigns, though Anthropic cautioned the binders are a first step and not drugs.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- An Anthropic mathematician says Claude helped prove the Riemann hypothesisSaturday, November 21, 2026
- Anthropic closes its IPO and the extra-share optionFriday, November 20, 2026
- Anthropic shares open at $111.50Thursday, November 19, 2026
- Musk says Anthropic may want 10 more gigawatts from SpaceXThursday, November 19, 2026
